Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.

about

Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.

Item

http://www.wikidata.org/entity/Q47405816

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacokinetics of intravitre ...... versus non-vitrectomized eyes.

@en

Pharmacokinetics of intravitre ...... versus non-vitrectomized eyes.

@nl

type

Item

label

Pharmacokinetics of intravitre ...... versus non-vitrectomized eyes.

@en

Pharmacokinetics of intravitre ...... versus non-vitrectomized eyes.

@nl

prefLabel

Pharmacokinetics of intravitre ...... versus non-vitrectomized eyes.

@en

Pharmacokinetics of intravitre ...... versus non-vitrectomized eyes.

@nl

P1476

Pharmacokinetics of intravitre ...... versus non-vitrectomized eyes

@en

P2093

Julie Connolly

http://www.w3.org/2001/XMLSchema#string

Magdalena Edington

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Defining response to anti-VEGF therapies in neovascular AMD

Ranibizumab for neovascular age-related macular degeneration

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.

Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data.

A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Intravitreal bevacizumab for the treatment of refractory diabetic macular edema.

Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results.

P304

1217-1224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17425255.2017.1404987

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ngaihang Victor Chong

P577

2017-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29134820

http://www.w3.org/2001/XMLSchema#string